COST-EFFECTIVENESS OF RIVAROXABAN WITHIN SUBGROUPS FOR ATRIAL FIBRILLATION AND VENOUS THROMBOEMBOLISM IN THE NETHERLANDS

被引：0
|
作者：
Gout-Zwart, J. [1 ]
Sediq, A. [1 ]
van den Bosch, M. [2 ]
Postma, M. J. [1 ]
机构：
[1] Univ Groningen, Groningen, Netherlands
[2] Bayer BV, Mijdrecht, Netherlands
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1758
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV90
引用
收藏
页码：A652 / A652
页数：1
相关论文
共 50 条
  • [21] The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands
    van Hulst, Marinus
    Stevanovic, Jelena
    Jacobs, Maartje S.
    Tieleman, Robert G.
    Kappelhoff, Bregt
    Postma, Maarten J.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (01) : 38 - 46
  • [22] Reply to the comment on "Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting''
    Morais, Joao
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2015, 34 (11) : 707 - 708
  • [23] Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
    Ye Wang
    Feng Xie
    Ming Chai Kong
    Lai Heng Lee
    Heng Joo Ng
    Yu Ko
    Cardiovascular Drugs and Therapy, 2014, 28 : 575 - 585
  • [24] Cost-effectiveness of antiarrhythmic drugs for prevention of thromboembolism in patients with paroxysmal atrial fibrillation
    Sakurai, M
    Ikeda, K
    Kuga, K
    Watanabe, I
    Yagi, H
    Atarashi, H
    Nakazata, Y
    Murakawa, Y
    Suzuki, F
    Mitamura, H
    Nozaki, A
    Sugi, K
    Sakurada, H
    Kobayashi, Y
    Kato, R
    Inoue, H
    Fujiki, A
    Horie, M
    Bando, S
    Chishaki, A
    Saikawa, T
    Okumura, K
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 2001, 65 (09): : 765 - 768
  • [25] Cost-effectiveness of rivaroxaban for the treatment of pulmonary embolism and secondary prevention of venous thromboembolism - a UK perspective
    McLeod, E.
    Guillermin, A.
    Hudson, R.
    Bamber, L.
    Muston, D.
    Lensing, A. W. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 90 - 90
  • [26] Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: A US perspective
    Seaman, Craig D.
    Smith, Kenneth J.
    Ragni, Margaret V.
    THROMBOSIS RESEARCH, 2013, 132 (06) : 647 - 651
  • [27] COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN IN PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT IN SLOVAKIA
    Lukac, M.
    Bielik, J.
    Lees, M.
    Foltan, V
    Tomek, D.
    VALUE IN HEALTH, 2010, 13 (07) : A520 - A520
  • [28] PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM IN HIP FRACTURE SURGERY - TOTAL COSTS AND COST-EFFECTIVENESS IN THE NETHERLANDS
    MOL, WEM
    EGBERTS, TCG
    PHARMACOECONOMICS, 1994, 5 (01) : 48 - 55
  • [29] PROPHYLAXIS OF VENOUS THROMBOEMBOLISM - ANALYSIS OF COST-EFFECTIVENESS
    SALZMAN, EW
    DAVIES, GC
    ANNALS OF SURGERY, 1980, 191 (02) : 207 - 218
  • [30] COST-EFFECTIVENESS OF VENOUS THROMBOEMBOLISM PROPHYLAXIS IN SURGERY
    BERGQVIST, D
    EUROPEAN JOURNAL OF SURGERY, 1994, : 49 - 53
12345